Kera Capital Partners Inc. Invests $1.41 Million in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)

Kera Capital Partners Inc. purchased a new stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 376,131 shares of the company’s stock, valued at approximately $1,407,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in KYTX. Bank of New York Mellon Corp bought a new stake in shares of Kyverna Therapeutics in the 2nd quarter valued at approximately $418,000. Rhumbline Advisers purchased a new stake in Kyverna Therapeutics during the 2nd quarter valued at $150,000. Federated Hermes Inc. bought a new stake in Kyverna Therapeutics in the second quarter worth $120,000. XTX Topco Ltd purchased a new position in Kyverna Therapeutics during the second quarter worth $625,000. Finally, Skandinaviska Enskilda Banken AB publ increased its position in Kyverna Therapeutics by 55.8% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 26,195 shares of the company’s stock valued at $196,000 after acquiring an additional 9,385 shares during the last quarter. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Stock Down 2.9 %

Shares of NASDAQ KYTX opened at $3.33 on Friday. Kyverna Therapeutics, Inc. has a twelve month low of $3.24 and a twelve month high of $35.06. The business has a fifty day simple moving average of $4.32 and a two-hundred day simple moving average of $5.99.

Kyverna Therapeutics (NASDAQ:KYTX) last released its quarterly earnings data on Wednesday, November 13th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.01. The business had revenue of $0.01 million during the quarter. As a group, sell-side analysts expect that Kyverna Therapeutics, Inc. will post -3.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Rodman & Renshaw initiated coverage on shares of Kyverna Therapeutics in a report on Wednesday, October 9th. They issued a “buy” rating and a $16.00 target price for the company. UBS Group began coverage on shares of Kyverna Therapeutics in a research note on Thursday, October 10th. They issued a “buy” rating and a $13.00 price objective for the company. HC Wainwright cut their target price on Kyverna Therapeutics from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. RODMAN&RENSHAW raised Kyverna Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 9th. Finally, Wells Fargo & Company cut their price objective on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, November 15th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $25.71.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.